High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors

Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-fr...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1998-05, Vol.77 (10), p.1672-1676
Main Authors: Lyttelton, MPA, Newlands, ES, Giles, C, Bower, M, Guimaraes, A, O'Reilly, S, Rustin, GJS, Samson, D, Kanfer, EJ
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carboplatin - administration & dosage
Carboplatin - adverse effects
Chemotherapy
clinical-oncology
Disease-Free Survival
Drug Resistance
Epidemiology
Germinoma - drug therapy
Glomerular Filtration Rate
Humans
Male
Medical sciences
Molecular Medicine
Oncology
Pharmacology. Drug treatments
Prognosis
Time Factors
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1998.275